Purple Biotech (PPBT.TA) Stock Price

Purple Biotech Price

CLOSED
0.00
​
Market closed

Revenue at Purple Biotech has contracted by 4.2% per year over the past 11 years to 1.00 M USD. Purple Biotech's net margin stands at -585.0%, up from -12,272.0% several years earlier. Purple Biotech currently offers a dividend yield of about 765,608,996.90%.

Purple Biotech stock price

Access this data via the Eulerpool API

Purple Biotech business model & stock analysis

Purple Biotech Ltd. is a development stage pharmaceutical company, which engages in drug development. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The firm is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Frequently asked questions about Purple Biotech

Converted at the current exchange rate, the Purple Biotech share trades at 0.00 EUR (0.00 USD).

The revenue cannot currently be calculated for Purple Biotech.

The profit cannot currently be calculated for Purple Biotech.

The P/E ratio cannot be calculated for Purple Biotech at the moment.

The P/S cannot be calculated for Purple Biotech currently.

The Eulerpool Quality Score for Purple Biotech is 2/10.

The ISIN of Purple Biotech is IL0007650166. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Purple Biotech is PPBT.TA. The ticker symbol is used to trade Purple Biotech shares on the stock exchange.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Sep 3, 1978
ISIN
IL0007650166
Cusip
M8S82A107
Market capitalization
60,576.85 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2025
—
P/Ee 2026
—
P/Ee 2027
—
P/S
P/Se
—
EV/EBIT
0.66
P/B Ratio
0.00
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-21.91 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
765.61 M %
Payout Ratio
0.00 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
25.00 %
Last updated Oct 10, 2026, 11:37 PM

Purple Biotech Peer Group

Purple Biotech FIGI

PPBT:IT · BBG000JYS3Z9KITVF:PQ · BBG00WHNVX67KITVF:UV · BBG00WHNVX76

All fundamentals and in-depth analysis of Purple Biotech

Our stock analysis for Purple Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Purple Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.